Piyanuch Kongtim

Objective Hemophagocytic lymphohistiocytosis (HLH) is a rare life‐threatening, hyperinflammatory syndrome usually treated with high‐dose steroids (HDS), often complemented with adjunct therapies, such as etoposide (HLH‐94 protocol). Anakinra has been reported to effectively treat HLH; however, has not been comparatively examined with etoposide‐based therapies. We sought to evaluate the effectiveness and durability of these treatment approaches. Methods We performed a retrospective analysis of all adult patients diagnosed with secondary HLH between January 2011 and November 2022 who received anakinra and HDS, the HLH‐94 protocol, HDS alone, or supportive care. Results Thirty adult patients with secondary HLH were included. Cumulative incidence (CI) of response at 30 days was 83.3%, 60%, and 36.4% for patients treated with anakinra, the HLH‐94 protocol, and HDS alone, respectively. CI of relapse at 1 year was 50%, 33.3%, and 0% with the HLH‐94 protocol, HDS, and anakinra and HDS, respectively. Overall survival at 1 year was higher with anakinra and HDS compared to the HLH‐94 protocol, yet was not statistically significant (77.8% vs. 33.3%; hazard ratio: 0.29; p = .25). Conclusion Treatment with anakinra and HDS in adults with secondary HLH was associated with higher response rates with longer survival compared with alternative therapies and should be further investigated in this setting.